or Try an Advanced Search...

    Technical Analysis for AUPH - Aurinia Pharmaceuticals Inc

    Grade Last Price % Change Price Change
    C 8.24 1.35% 0.11
    AUPH closed up 1.35 percent on Wednesday, November 20, 2024, on 1.11 times normal volume.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Flat
    Historical AUPH trend table...
    Date Alert Name Type % Chg
    1,2,3 Pullback Bullish Bullish Swing Setup 1.35%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.35%
    NR7 Range Contraction 1.35%
    NR7-2 Range Contraction 1.35%
    1,2,3 Pullback Bullish Bullish Swing Setup 2.87%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.87%
    NR7 Range Contraction 2.87%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.08%
    Calm After Storm Range Contraction -1.08%
    Inside Day Range Contraction -1.08%
    Older End-of-Day Signals for AUPH ...

       Recent Intraday Alerts

    Alert Time
    Up 1% about 19 hours ago
    Non-ADX 1,2,3,4 Pullback Entry about 20 hours ago
    1,2,3, Pullback Entry about 20 hours ago
    Rose Above Previous Day's High about 20 hours ago
    60 Minute Opening Range Breakout about 20 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    AUPH Chart by TradingView
    Basic chart:

    Profile

    Aurinia Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development of a therapeutic drug to treat autoimmune diseases in Canada. The company's lead drug includes Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has a development and license agreement with 3SBio Inc. for the clinical development, registration, and commercialization of voclosporin in China; and licensing and collaboration agreement with Vifor Pharma for the treatment of lupus and various proteinuric nephrology indications. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Life Sciences Drugs Autoimmune Disease Clinical Development Lupus Peptides Nephrology Immunosuppressants Lupus Nephritis Nephritis

    Is AUPH a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 18 Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
    Nov 15 Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
    Nov 14 Aurinia to Participate in Jefferies London Healthcare Conference
    Nov 8 Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon
    Nov 8 Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets
    Nov 8 Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
    Nov 7 Aurinia stock jumps 14% on Q3 earnings, restructuring announcement
    Nov 7 Aurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Call Transcript
    Nov 7 Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates
    Nov 7 Aurinia: Q3 Earnings Snapshot
    See more AUPH news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 9.725
    52 Week Low 4.71
    Average Volume 1,148,996
    200-Day Moving Average 6.08
    50-Day Moving Average 7.35
    20-Day Moving Average 7.77
    10-Day Moving Average 8.26
    Average True Range 0.32
    RSI (14) 63.90
    ADX 31.03
    +DI 29.66
    -DI 14.26
    Chandelier Exit (Long, 3 ATRs) 7.79
    Chandelier Exit (Short, 3 ATRs) 7.80
    Upper Bollinger Bands 8.80
    Lower Bollinger Band 6.74
    Percent B (%b) 0.73
    BandWidth 26.49
    MACD Line 0.30
    MACD Signal Line 0.29
    MACD Histogram 0.0128
    Fundamentals Value
    Market Cap 1.18 Billion
    Num Shares 144 Million
    EPS -0.54
    Price-to-Earnings (P/E) Ratio -15.26
    Price-to-Sales 7.49
    Price-to-Book 3.04
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 8.77
    Resistance 3 (R3) 8.71 8.49 8.68
    Resistance 2 (R2) 8.49 8.35 8.51 8.65
    Resistance 1 (R1) 8.36 8.27 8.43 8.42 8.62
    Pivot Point 8.14 8.14 8.17 8.16 8.14
    Support 1 (S1) 8.01 8.00 8.08 8.07 7.86
    Support 2 (S2) 7.79 7.92 7.81 7.83
    Support 3 (S3) 7.66 7.79 7.80
    Support 4 (S4) 7.72